This report provides you with real-time intelligence on the Chinese herbicide market. It is a monthly newsletter and can be downloaded in PDF format. The subscription period is annually, and a total of 12 subscriptions are granted to subscribers.
In recent years, China’s herbicide output has increased rapidly, which has promoted the growth of domestic and export market demand. The output will continue to grow in the next few years.
However, the industry still faces many long-term challenges, including low market concentration, poor R&D investment, increased costs due to China’s strict environmental regulations, and increased crop tolerance to key products such as glyphosate.
Herbicide China News will help you maintain a leading position in this rapidly changing market by reporting the entire herbicide industry chain from raw materials to final consumption in real time.
The latest market data, including price information of raw materials, intermediates and final products, import and export data, production, consumption, operating rates, etc.
In-depth analysis of market trends, Chinese government policies, the performance of leading Chinese manufacturers, mergers and acquisitions, new technologies, etc.
Expert commentary from industry insiders, including regular guest articles and interviews with insiders from leading Chinese manufacturers, associations and government organizations
EST office hours call 1-917-300-0470 US/Canada toll free 1-800-526-8630 GMT office hours call +353-1-416-8900
Greed was finally blown away, and prudence was rehabilitated. I now see three barrels of stock attract me.
In the investment game, not only the purchased goods but also the purchased goods are involved. This is about when you bought it. “Buy at a low price” is one of the most common advice on Wall Street and is touted as a tried and tested strategy. Of course, the strategy seems simple. Under the influence of multiple factors such as earnings results and the macro environment, stock prices will naturally fluctuate. Investors try to time the market and determine when the stock bottoms out. However, in practice, implementing this strategy is by no means an easy task. The most important thing is, given the turbulent market conditions in the past few weeks, how should investors measure when a name is in a trough? These professional stock selectors have identified three high-profile stocks whose current stock prices are close to their 52-week lows. Analysts noticed that each product will rebound on an upward track, and analysts see an attractive entry point. Using the TipRanks database, we found that the analyst consensus rated these three as “strong buys,” and they also have huge upside potential. Progenity (PROG) provides clear and feasible genetic results, and Progenity specializes in providing testing services . The company began trading on the Nasdaq in June, and its share price has fallen 44% since. The share price changed hands at $8.11 per share, and several members of Wall Street suggested to pull it away before the trigger. Piper Sandler analyst Steven Mah pointed out that even in the context of COVID-19, PROG can still Achieve the results for the second quarter of 2020. Analysts pointed out: “We are driven by non-invasive prenatal testing (NIPT) and carrier screening. At the end of the second quarter of 2020, we resumed 75,000 tests (approximately 79,000 in the first quarter of 2020), which makes us feel Encouragement.” Mah explained in detail, “Progenity did not provide guidance, but the test volume in June reached 28,000 (an average of ~26,000 per month in the first quarter of 2020). We believe this proves its reproductive test The durability of Progenity and the success of Progenity in the collaboration-marketing and attaching carrier screening to the more important NIPT. It is worth noting that despite the pandemic, Progenity is able to maintain its leading COVID test turnaround Time.” In addition, due to the pandemic, health insurance company Aetna temporarily extended the coverage of average high-risk NIPT to the end of the year. Mah believes that, given its clinical utility, the American College of Obstetricians and Gynecologists (ACOG) also hopes to recognize the average risk in the future. The fourth NIPT (Single Molecule Count) test can measure the fetal fraction, Mah said that this is an important milestone and will continue to develop into 2021. Since the technology may be applied to DNA, RNA, epigenetic markers and proteins for other clinical applications (such as oncology), analysts look forward to the completion of the technology. Pre-eclampsia verification and possible 2H21 release in the fourth quarter of 2020. The analyst added: “We believe that pre-eclampsia (the serviceable market is about $2.3 billion) is a major difference for Progenity, allowing them to cross-sell throughout the entire reproductive test process.” If it is not enough, PROG Will sign its first GI In August, Precision Medicine reached a partnership agreement with a top 20 pharmaceutical company. The Oral Biological Therapy Delivery System (OBDS) is a combination of ingestible drugs and equipment designed to accurately and systematically deliver biological agents to the submucosal tissues of the small intestine through needle-free liquid jet injection as part of the collaboration. Mah said: “We think Progenity can sign more pharmaceutical deals and look forward to the news flow in this area.” Mah said: “Given the strong recovery of the core testing business, we think Progenity’s stock is undervalued. For this reason, Mah Rating PROG as “overweight” (ie, “buy”) and a target price of $17. If his paper is published, his twelve-month earnings will reach 105%. (To view Mah’s track record, please Click here) Do other analysts agree? They are. In fact, only 4 “buy” ratings have been issued in the past three months. Therefore, the message is clear: PROG is a strong buy. Given the average price of $13.33 Target, the stock price may rise by 60% next year. (Please refer to the PROG stock analysis on TipRanks) Tactile System Technology (TCMD) Tactile System Technology hopes to develop new treatments for lymphedema, which is caused by damage to the lymphatic system. It occurs when it disrupts normal fluid transport in the body, and chronic venous insufficiency. It has fallen 52% year-to-date, and its share price of $32.67 is close to a 52-week low of $29.47. Therefore, as business trends improve, Wall Street is in fierce competition Analyst Cecilia Furlong admitted in writing for Canaccord that this pandemic has hindered the company’s development because COVID-19 has had an impact on both volume and sales. In the next March For half a month, the number has fallen by 50% compared to the first half of this month, and the number of patients in TCMD in April and May is still being challenged. Having said that, the trend started to improve at the end of May. Furlong explained that relative to TCMD has experienced a greater rebound in the overall medical technology volume trend. TCMD has further benefited from its expanded use of technology, allowing it to remotely interact with clinicians and provide support to patients.” The analyst added, “In addition, some providers The latest trend is to prescribe Flexitouch (an advanced intermittent pneumatic compression device that can self-manage lymphedema and varicose vein nonhealing) as early as possible in the treatment process to reduce face-to-face contact, provide upside space in a short time, and have Perhaps most importantly for the transition, Furlong is also optimistic about the priorities of the new CEO Dan Reuvers and the company’s investors. Tons and market development efforts. TCMD will shift its focus from its acquired Airwear product line to its Flexitouch and Entre (a pneumatic compression device used to assist in the home management of chronic swelling and venous ulcers related to lymphedema and chronic venous insufficiency).” Given the serious penetration of the lymphedema/venous lymphedema market targeted by Flexitouch Inadequate, at the same time, the company’s Head&Neck platform is aimed at a large group of patients. At present, treatment options are limited. We believe that the combination of education and clinical data is an improvement To develop and penetrate key markets for these diseases… Looking ahead, we hope that management will continue to collect an extensive clinical data base to support reimbursement and promote widespread adoption. “All this prompted Furlong to maintain a buy rating on the stock and a target price of $62. This target expresses her confidence in TCMD’s ability to soar 90% next year. (To view Furlong’s track record, click here .) Usually, other analysts are on the same page. With 3 buy ratings and 1 hold rating, Wall Street says that TCMD is a strong buy. The average price target of $62.33 gives the stock price 91% upside. Finally, (But not least, we have uniQure, which provides curative gene therapy that may change the lives of patients.) Although the stock price has fallen 44% so far this year to $40, although it is not higher than the 52-week low Point 36.20 dollars, but many analysts still have high hopes. Five-star analyst Joseph Schwartz admitted on behalf of SVB Leerink that the stock price has been struggling after the news broke. He and CSL Behring reached an agreement on Aure-B’s gene therapy Aure-AMT-061 The cooperation and licensing agreement broke down, he argued that “as investors and Qure shift their focus to its next-generation AMT-130, the basic turnover of its shareholders may now be completed. Schwartz further added: “Because the current merger premium is no longer sufficient We believe that the current level of QURE is an attractive purchase opportunity for investors interested in the company’s emerging CNS gene therapy., The agreement with CSL Behring is closer, and QURE will be responsible for completing the key phase 3 HOPE-B trial and manufacturing process. According to the management, the 26-week factor IX (FIX) data of all 54 patients who participated in the trial is still in a normal state, and the main data of the key trial is still expected to be read by YE20. It should be mentioned that in the Phase 2b dose confirmation study, QURE reported that FIX activity reached 41% within one year. In addition, Schwartz pointed out that as HOPE-B proceeds as planned, QURE is expected to be available in the United States and the European Union in 2021. Validation of the manufacturing process will continue before submitting the BLA/MAA application. Eligible to receive more than US$2 billion in funding, including an upfront cash payment of US$450 million, US$1.6 billion in regulatory and commercial milestones, and double-digit concessions The use fee can be up to 20% of the net sales of the product. The funds are strong and can rapidly develop CNS assets, including AMT-130 (for Huntington’s disease (HD) AAV5 gene therapy) and AMT-150 (for use AAV gene therapy for type 3/SCA3 spinocerebellar ataxia)…We still believe that as QURE’s CNS pipeline matures, the company may once again become an attractive collaboration for large biopharmaceutical companies Partners, these large biopharmaceutical companies have recently acquired many publicly traded gene therapy platforms with strong manufacturing capabilities,” Schwartz pointed out. g QURE’s efforts persuaded Schwartz to reiterate its outperform (ie buy) rating. While calling options, he also set a price target of $67, implying that the stock has 68% upside from current levels. (To see Schwartz’s track record, click here) What else to say on Wall Street? Nine buys and three holds were issued in the last three months, so the consensus rating is strong buy. In addition, the average price target of $69.89 also shows a 75% upside. (See QURE Stock Analysis on TipRanks) To find great ideas for trading low-priced stocks with attractive valuations, visit TipRanks’ Best Buys Buy, a newly launched tool that combines all the stock insights from TipRanks in together. This article is only an article by selected analysts. The content is for reference only. Before making any investment, it is very important to conduct your own analysis.
Tesla’s leadership in electric vehicle technology has made other automakers desperately catch up.
Join HSBC Premier Banking now and enjoy a welcome reward of up to HK$16,200. Subject to terms and conditions.
An analyst at UBS warned that although Apple stocks usually outperform the market before the iPhone goes public, they usually underperform after the listing.
One of the easiest ways to ensure you invest in a stable company is to pick the large stocks that dominate its market. Here are nine large stocks that can provide generous (and more importantly sustainable) dividends. In many ways, Pfizer is the birthplace of large stocks with scale, stable income and endurance.
With a monthly premium of as low as $500, [Cigna Premium Medical Insurance] has an annual medical benefit of up to $38.8 million, which fully covers medical expenses.
Gold is falling below expectations from a triangle. It is expected to fall for 1-2 weeks to the next 6-month low. From that lowest point to late December, it may rebound to more than $2,300, depending on the election (or lack of elections) in November.
From 2013 to 2019, 13.2 million new pickup trucks were sold in the United States, and the monthly payment for each pickup truck was as high as $1,300. Ben Carlson said the money is best used for 401(k) or IRA payments.
“It’s hard to think of the possibility of saving too much, but diligent savers and investors can sometimes reach their savings goals before the actual retirement date,” said Kali Hassinger, a certified financial planner at the Center for Financial Planning (Inc). In Southfield, Michigan. After reaching their goals, super savers may exceed the lifestyle of retirees. Hasinger said: “According to a rule of thumb, how much income should be saved, but there is no one-size-fits-all total savings or threshold.”
Without any experience, Kyle Dennis (Kyle Dennis) decided to invest in stocks. His trading success is attributed to these strategies.
(Bloomberg)-Tesla’s highly anticipated “Battery Day” failed to meet expectations, which helped to drive its market value soaring by $320 billion this year. Elon Musk outlined ambitious goals, which will take time achieve. The official made a plan on Tuesday to produce a $25,000 car in the next three years and cut battery costs in half. Analysts said that although the technology and manufacturing innovations outlined are impressive, Tesla’s valuation has already reflected its destructive power, and the lack of surprises in the hyped battery display event may disappoint investors. The company’s stock price fell 11% to 375.88 US dollars, closing price in New York is 380.36 US dollars. So far, they have risen by about 360%. “Considering “Battery Day”, we believe that there is a lack of upcoming catalysts and we are cautious about demand in an economic downturn,” Robert W. Baird’s Ben Kallo Write. UBS (UBS) analyst Patrick Hummel rated this stock as “Neutral”. In his research report, he said that Tesla’s leadership in battery technology and cost has been given full attention stock. He wrote: “Given that people have high expectations for the event, we think the market will first react negatively to the relatively long innovation time and lack of sophistication.” 49-year-old Musk said that Tesla eventually Hope to produce 20 million cars every year. He introduced a series of innovations, including the use of dry electrode technology and making the battery a structural element of the car. These growth and long-term progress masked people’s expectations for the Great Leap Forward, and Musk himself showed a huge leap in the weeks before the game. “The challenge for stocks is that everything they talk about has been three years old,” Gene said. Munster (Louns Ventures) Managing Director. “Improvements in vertical integration-from producing its own batteries on the trial production line at the Fremont, California plant, to having the rights to lithium, there have been improvements in vertical integration. The clay deposits in Nevada are designed to allow Tesla Cut costs and provide cheap cars in 2023. “From the beginning, this has been our dream,” Musk said at an event related to Tesla battery technology. “About three years from now, we are confident A convincing electric car with a value of $25,000 can be manufactured, and the car can also be fully autonomous. “Reducing battery costs Musk has been mocking the prospect of cheaper, mysterious models, but has not really fulfilled his long-term price of $35,000. Promises for the Model 3. Three years after Tesla began accepting car orders in early 2016, The CEO announced plans to close most of Tesla’s stores to save costs and enable him to provide cars at this cost. He looked back after 10 days and now the cheapest Model 3 is priced at $37,990. Manufacturing Real To increase Tesla’s current annual output to 20 million vehicles, it will require much more batteries than the batteries produced by a handful of suppliers in the world. Therefore, Musk plans to supplement it by internally manufacturing batteries. Purchased products to expand global production capacity. “Today’s batteries are not expanding fast enough,” Musk said, partly because of the need to find sustainable energy. “There is a clear path to success, but there is a lot of work to do. Musk said that gasoline-powered internal combustion engines will one day become obsolete. Carnegie Mellon University battery expert Venkat Viswanathan said that Musk described “a series of incredible innovations of varying difficulty.” Viswanathan believes that although battery manufacturing technology is Progress is feasible and deliverable within three years, but the development of chemical technology will take longer. If the planned innovation can be paid off, the vehicle mileage will increase by 54%, the cost may be reduced by 56%, and large investments Factory. Tesla’s senior vice president of powertrain and energy engineering Andrew Bagrino said that the price may fall by 69%. Bloomberg NEF estimates that Tesla’s battery pack price in 2019 will be $128/kWh A 56% cost reduction will bring the price to $56/kWh. Musk said that in addition to the trial production line for battery pack batteries in Fremont, the company will also produce batteries at a plant under construction in Berlin. A leap in “battery packs” Most global automakers have avoided the idea of ​​making their own battery packs. Musk said in a tweet on Monday that Tesla will need to start producing its own batteries to support Tesla For automobiles, the investment cost is high, and they lack expertise in an industry dominated by Asian electronics manufacturers (such as Panasonic and LG Chemical Co., Ltd.). Various products, even if it increases procurement from external suppliers. He Wrote that the company expects a severe battery shortage by 2022 and beyond, unless it increases its own battery production. “I am very surprised that they are making this leap by themselves,” Tony, a consultant in charge of GM R&D · Tony Posawatz said. Motors Co.’s plug-in hybrid Chevrolet Volt is now a board member of Tesla’s competitor Lucid Motors Inc. “I think it’s going to be a little harder than they thought. And I don’t think we will see a lot of sales for a long time. “Tesla’s most important long-term partner in the battery field is Panasonic, headquartered in Osaka, but it has also signed smaller-scale agreements with Contemporary Amperex Technology Co. (CATL) in Fujian Province, China and LG Chem in South Korea. The agreement. Read more: LG Chem, Panasonic, and Tesla hope to reduce battery costs. The battery day presentation included several pieces of news that were overshadowed by the discussion of the positive electrode and electrolyte. An example: the “grid of the Model S sedan” “The version-with a range of 520 miles-can be ordered now, although the vehicle is not expected to go on sale until the second half of 2021. The annual shareholder meeting held outdoors to achieve social distancing. Shareholders sit in Musk’s parking lot. On Sla Motors, shouting instead of cheering as Musk said. Investors voted to re-elect Musk and Chairman Robin Denholm as members of the board of directors, and voted against those who demand increased human rights in the supply chain Transparency resolutions and arbitration with employees. A shareholder resolution requiring Tesla to pass a simple majority vote was indeed passed. Musk told shareholders that he expected deliveries to increase by about 30% to 40% this year, reiterating Tesla’s forecast as automakers struggle to recover. From the coronavirus pandemic. Tesla said it expects to deliver 500,000 vehicles by 2020, an increase of approximately 36% from 2019. Tesla said it expects to arrive 500,000 cars will be delivered in 2020. In July, the electric car manufacturer said it had achieved this goal. It will be “more difficult” due to the pandemic-related production suspension earlier this year. According to research company LMC Automotive, this year Global sales are expected to drop by about 17% from last year’s 90 million vehicles to 75 million vehicles (the closing price update in the third paragraph). For more similar articles, please visit Bloomberg.com Now to keep up with the most trusted business news source. ©2020 Bloomberg LP
(Bloomberg)-The search for renewable energy stocks caused an obscure company to soar by more than 4000% in one day, despite the small number of stocks on the market. SPI Energy Co.’s trading price surged on Tuesday. After starting a department on Wednesday to design and develop electric vehicles and charging solutions, the stock price was as high as $47 per share. This new department is called EdisonFuture and seems to be inspired by Thomas Edison and his competition with the scientist, whose name has been cited by two companies in the electric vehicle field, Nikola Corp. and Tesla Inc. As of Wednesday’s trading day, SPI stock rose 1,237. Earnings per share reached $14 and triggered at least seven volatility trading suspensions within four hours. The trading volume on Wednesday exceeded 340 million shares, more than 700 times the normal trading volume. According to data compiled by Bloomberg, the company has approximately 14.8 million shares issued and approximately 7.4 million shares outstanding. The company’s CEO Peng Xiaofeng said in a statement on Wednesday: “As our diversified solar business increases electric vehicles and electric vehicle charging businesses, we position SPI Energy in the future of renewable energy.” Electric vehicles in Nigeria The company’s founder recently resigned due to accusations of misleading investors. SPI is headquartered in Santa Clara, California and has operations in Asia, Europe, North America and Australia (latest closing price). Please visit Bloomberg.com to visit us and subscribe now to stay ahead of the most trusted business news source. ©2020 Bloomberg LP
Bloomberg-Amazon.com Inc. told Echelon Fitness to stop selling exercise bikes developed and branded in cooperation with the e-commerce giant. Echelon announced the EX-Prime Smart Connect Bike earlier this week. Said it was “developed in cooperation with Amazon.” The machine is listed on Amazon.com at a price of $500, which is a significant discount to the machine sold by Peloton Interactive Inc. “This bike is not an Amazon product, nor is it related to Amazon Prime,” an Amazon spokesperson wrote in an email on Tuesday night. “Echelon does not have a formal partnership with Amazon. We are communicating with Echelon to clarify this, stop product sales, and change product brands.” Amazon’s Prime subscription is one of the most successful products, the service Free shipping and other additional fees are charged annually. In the history of e-commerce. Products related to the program can often boost sales, especially on Amazon.com. Echelon did not immediately respond to a request for comment. However, the company announced that the original press release for bicycles will no longer be available online on Tuesday night. On Amazon’s website, the product is also listed as “currently unavailable.” Fearing about Amazon’s new competition, Peloton’s stock fell 6.7% earlier on Tuesday. But the stock price fell less than 1% at the close in New York. “Except for some cosmetic changes, the $500 bike is almost identical to Echelon’s $500 bike on Walmart.com. The product has been on Walmart.com since 2000. There was no significant increase in Peloton in March. Impact,” KeyBanc Capital Markets analyst Edward Yruma wrote in a report to investors. (The update shows that the Echelon press release is no longer available in the fifth paragraph) For more similar articles, please visit us and subscribe now to stay ahead of the most trusted business news source. ©2020 Bloomberg LP
Guaranteed average dividend payout of 2.6%pa at any time to surrender the insurance $ 0 handling fee! Savings start as low as $4,000. You can get a $200 supermarket cash coupon if you successfully apply for a limited time offer!
Two participants told Reuters that Wells Fargo CEO Charles Scharf recently angered black employees at a Zoom (ZM) meeting last summer, saying that there were not enough qualified minority applicants to realize the company Diversification goals. Sharf’s speech follows a memo that was also sent to Wells Fargo (WFCs) employees this summer. Reuters reported that he hinted that the Currency Center Bank could not find qualified black talent to fill the company’s vacancies. In a memo quoted by Reuters on June 18, Schalf wrote: “Although this sounds like an excuse, the unfortunate reality is that the recruitment of black talent is very limited.”
According to the Wall Street Journal, negotiations between electric truck manufacturer Nikola and several potential partners to establish hydrogen fueling stations have stalled.
Nvidia this week with strong earnings and bold moves grabbed the market share of smartphones and data centers, and entered the buying zone of strong transactions.
The COVID-19 disease has spread globally, and many countries have been hit by other deadly infectious diseases at the same time. Act now to deal with multiple diseases with MSF!
After Trevor Milton, an electric truck entrepreneur, stepped down on Monday to become the executive chairman and board member of his newly listed company Nikola, legal issues have now surfaced.
XL fleet management has a niche commercial vehicle strategy that can enter the market through its EV powertrain.
After the company announced that it would start an electric vehicle subsidiary, SPI Energy’s stock soared 3,100% in intraday trading on Wednesday. According to FactSet data, the stock price of SPI Energy, which is said to provide photovoltaic solutions for commercial, residential, government and utility customers and investors, traded at $33.53 per share after closing at $1.05 on Tuesday. The data shows that the company’s stock surge has pushed its market value from approximately US$15 million to approximately US$460 million. The company said on Wednesday that it launched its wholly-owned subsidiary EdisonFuture, which aims to design and develop electric vehicles and EV charging solutions. This will allow the company to compete with companies such as Tesla Inc., one of the most popular electric car manufacturers on the planet, and its own manufacturer of electric car batteries. Peng Xiaofeng, CEO of SPI Energy, said in a statement: “As Tesla has shown, the end-to-end business model in the renewable energy sector can generate tremendous value. By adding EV and EV charging segments to our diverse In terms of business in the modernized solar industry, we position SPI Energy in the future of renewable energy.”